Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Western Sydney Local Health District
Ascentage Pharma Group Inc.
University of Maryland, Baltimore
Shenzhen BinDeBio Ltd.
Bay Area Gynecology Oncology
NHS Greater Glasgow and Clyde
Wuhan University